# reload+after+2024-01-20 05:44:01.082746
address1§One Main Street
address2§Suite 1350
city§Cambridge
state§MA
zip§02142
country§United States
phone§617 410 4650
website§https://www.cullinanoncology.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Cullinan Oncology, Inc. a clinical-stage biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally bioavailable small-molecule that is in a Phase IIb dose escalation for treating patients with non-small cell lung cancer. Its products also include CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors; and CLN-418, a human bispecific antibody that is in Phase 1 clinical trial for the treatment of solid tumors. In addition, the company's preclinical product includes CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. The company has collaboration agreements with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Oncology, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
fullTimeEmployees§62
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Nadim  Ahmed', 'age': 55, 'title': 'President, CEO & Director', 'yearBorn': 1968, 'fiscalYear': 2022, 'totalPay': 1137777, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Patrick A. Baeuerle Ph.D.', 'age': 65, 'title': 'Co-Founder, Chief Scientific Advisor & Chairman of Scientific Advisory Board', 'yearBorn': 1958, 'fiscalYear': 2022, 'totalPay': 763734, 'exercisedValue': 0, 'unexercisedValue': 3785044}, {'maxAge': 1, 'name': 'Mr. Jeffrey  Trigilio', 'age': 38, 'title': 'CFO & Treasurer', 'yearBorn': 1985, 'fiscalYear': 2022, 'totalPay': 727986, 'exercisedValue': 0, 'unexercisedValue': 745313}, {'maxAge': 1, 'name': 'Dr. Jennifer  Michaelson Ph.D.', 'age': 55, 'title': 'Chief Scientific Officer', 'yearBorn': 1968, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Jacquelyn L. Sumer J.D.', 'age': 44, 'title': 'Chief Legal Officer, Chief Compliance Officer & Corporate Secretary', 'yearBorn': 1979, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Rose  Weldon', 'title': 'Senior Vice President of Communications', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Steve  Andre', 'title': 'Chief Human Resources Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Corinne  Savill Ph.D.', 'age': 64, 'title': 'Chief Business Officer', 'yearBorn': 1959, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Jeffrey  Jones M.B.A., M.D., M.P.H.', 'age': 51, 'title': 'Chief Medical Officer', 'yearBorn': 1972, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Kevin A. Johnston', 'title': 'Chief Technical Operations Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§9
boardRisk§7
compensationRisk§9
shareHolderRightsRisk§8
overallRisk§8
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§0.198
currency§USD
dateShortInterest§1702598400
forwardEps§-4.11
exchange§NMS
quoteType§EQUITY
shortName§Cullinan Oncology, Inc.
longName§Cullinan Oncology, Inc.
firstTradeDateEpochUtc§1610116200
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§df7e2588-017b-3d57-acc4-780da62c5adc
gmtOffSetMilliseconds§-18000000
targetHighPrice§34.0
targetLowPrice§19.0
targetMeanPrice§24.6
targetMedianPrice§22.0
recommendationMean§1.7
recommendationKey§buy
numberOfAnalystOpinions§5
quickRatio§19.895
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
